循环低密度中性粒细胞与头颈部鳞状细胞癌抗PD1免疫治疗耐药相关
前瞻性观察性研究纳入25例经铂类方案后接受免疫治疗或化疗的头颈部鳞状细胞癌患者,分析低密度中性粒细胞与血清标志物。免疫治疗队列中高LDN水平者无进展生存期更短(1.8个月 vs 10.9个月,p=0.034),高IL7与更长总生存期相关(13.47个月 vs 3.51个月,p=0.013)。
要点
- 免疫治疗队列中高LDN水平者无进展生存期更短(1.8个月 vs 10.9个月,p=0.034)。
- 高IL7水平与显著更长的总生存期相关(13.47个月 vs 3.51个月,p=0.013)。
- 上述LDN与疗效的关联未在化疗患者中重现。
核心结论
- 高基线循环LDN和低IL7可能识别出对HNSCC单药ICI内在难治的患者亚群。
研究设计与样本
- 前瞻性观察性研究,纳入25例经铂类方案后接受免疫治疗或化疗的HNSCC患者,分析低密度中性粒细胞(LDNs)和血清标志物。
主要发现
- 免疫治疗队列中,高LDN水平患者无进展生存期更短(1.8个月 vs 10.9个月,p=0.034)。
- 进展者LDN百分比较非进展者高,但未达统计学显著(均值20.68% vs 4.095%,p=0.0875)。
- 上述发现在化疗患者中未重现。
- 高IL7水平与显著更长的总生存期相关(13.47个月 vs 3.51个月,p=0.013)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Identification of predictive biomarkers to Immune checkpoint inhibitors (ICIs) in head and neck cancer (HNSCC) is an unmet need. METHODS: This was a prospective observational study including 25 patients with HNSCC treated with immunotherapy or chemotherapy after a prior platinum-based regimen. Low density neutrophils (LDNs) and serum markers were analyzed. RESULTS: In the immunotherapy cohort, patients with high LDN levels had a shorter progression free survival (PFS) (1.8 months vs. 10.9 months; *p = 0.034). Also, progressors showed higher percentage of LDNs compared to non-progressors although significance was not reached (mean 20.68% vs. 4.095%, p = 0.0875). These findings were not replicated in patients treated with chemotherapy. High levels of interleukin-7 (IL7) were correlated with a significantly longer overall survival (OS) (13.47 months 3.51 vs. months, *p = 0.013). CONCLUSIONS: High baseline circulating LDNs and low IL7 could identify a subset of patients intrinsically refractory to ICIs as monotherapy in HNSCC.
引用
- Arrazubi V, Goñi S, González-Borja I, et al. Circulating low density neutrophils are associated with resistance to anti-PD1 immunotherapy in squamous head and neck cancer. Head Neck. 2023. PMID: 37792371. doi:10.1002/hed.27536
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。